Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oxidative stress from DGAT1 oncoprotein inhibition in melanoma suppresses tumor growth when ROS defenses are also breached.
Wilcock DJ, Badrock AP, Wong CW, Owen R, Guerin M, Southam AD, Johnston H, Telfer BA, Fullwood P, Watson J, Ferguson H, Ferguson J, Lloyd GR, Jankevics A, Dunn WB, Wellbrock C, Lorigan P, Ceol C, Francavilla C, Smith MP, Hurlstone AFL. Wilcock DJ, et al. Among authors: wellbrock c. Cell Rep. 2022 Jun 21;39(12):110995. doi: 10.1016/j.celrep.2022.110995. Cell Rep. 2022. PMID: 35732120 Free PMC article.
Heterogeneous tumor subpopulations cooperate to drive invasion.
Chapman A, Fernandez del Ama L, Ferguson J, Kamarashev J, Wellbrock C, Hurlstone A. Chapman A, et al. Among authors: wellbrock c. Cell Rep. 2014 Aug 7;8(3):688-95. doi: 10.1016/j.celrep.2014.06.045. Epub 2014 Jul 24. Cell Rep. 2014. PMID: 25066122 Free PMC article.
BRAF as therapeutic target in melanoma.
Wellbrock C, Hurlstone A. Wellbrock C, et al. Biochem Pharmacol. 2010 Sep 1;80(5):561-7. doi: 10.1016/j.bcp.2010.03.019. Epub 2010 Mar 27. Biochem Pharmacol. 2010. PMID: 20350535 Review.
Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma.
Smith MP, Ferguson J, Arozarena I, Hayward R, Marais R, Chapman A, Hurlstone A, Wellbrock C. Smith MP, et al. Among authors: wellbrock c. J Natl Cancer Inst. 2013 Jan 2;105(1):33-46. doi: 10.1093/jnci/djs471. Epub 2012 Dec 17. J Natl Cancer Inst. 2013. PMID: 23250956 Free PMC article.
Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.
Smith MP, Brunton H, Rowling EJ, Ferguson J, Arozarena I, Miskolczi Z, Lee JL, Girotti MR, Marais R, Levesque MP, Dummer R, Frederick DT, Flaherty KT, Cooper ZA, Wargo JA, Wellbrock C. Smith MP, et al. Among authors: wellbrock c. Cancer Cell. 2016 Mar 14;29(3):270-284. doi: 10.1016/j.ccell.2016.02.003. Cancer Cell. 2016. PMID: 26977879 Free PMC article.
Targeting MITF in the tolerance-phase.
Arozarena I, Smith MP, Wellbrock C. Arozarena I, et al. Among authors: wellbrock c. Oncotarget. 2016 Aug 23;7(34):54094-54095. doi: 10.18632/oncotarget.9423. Oncotarget. 2016. PMID: 27528022 Free PMC article. No abstract available.
65 results